Syntiron LLC Awarded a Qualifying Therapeutic Discovery Project (QTDP) Grant under the U.S. Patient Protection and Affordable Care Act of 2010

Published: Nov 12, 2010

SAINT PAUL, Minn.--(BUSINESS WIRE)--Syntiron, LLC, a private biotech company located in St. Paul, Minnesota, today announced the company was awarded a U.S. government grant under the Qualifying Therapeutic Discovery Project (QTDP) Program. Syntiron received the grant of $244,479 in support of its Bacterial Vaccine and Therapeutic Platform Technology, which includes the development of vaccines to prevent infections by Yersinia, Salmonella and Staphylococcus bacteria.

Back to news